A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055374 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was integrated into BRE-AD01-001 study

Conditions

Atopic Dermatitis

Interventions

DRUG: BxC-I17e
DRUG: Placebo

Sponsor

Brexogen Inc.